LEADER 05231nam 2200637 450 001 9910460135303321 005 20200520144314.0 010 $a1-118-88994-0 035 $a(CKB)3710000000365738 035 $a(EBL)1895710 035 $a(SSID)ssj0001437628 035 $a(PQKBManifestationID)12630170 035 $a(PQKBTitleCode)TC0001437628 035 $a(PQKBWorkID)11372766 035 $a(PQKB)10927176 035 $a(MiAaPQ)EBC1895710 035 $a(DLC) 2015000334 035 $a(Au-PeEL)EBL1895710 035 $a(CaPaEBR)ebr11026086 035 $a(CaONFJC)MIL770050 035 $a(OCoLC)899267729 035 $a(EXLCZ)993710000000365738 100 $a20150310h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aCardiovascular diseases $efrom molecular pharmacology to evidence-based therapeutics /$fY. Robert Li 210 1$aHoboken, New Jersey :$cJohn Wiley & Sons Inc.,$d2015. 210 4$dİ2015 215 $a1 online resource (504 p.) 300 $aIncludes index. 311 $a0-470-91537-4 320 $aIncludes bibliographical references and index. 327 $aTitle Page; Copyright Page; Contents; Preface; List of Abbreviations; Unit I General Introduction; Chapter 1 Introduction to Cardiovascular Diseases; 1.1 Overview; 1.2 Definition of Cardiovascular Diseases; 1.3 Classification of Cardiovascular Diseases; 1.3.1 Classification Based on Anatomical Location; 1.3.2 Classification Based on the Involvement of Atherosclerosis; 1.3.3 Total Cardiovascular Diseases and ICD-10 Classification; 1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases; 1.4.1 NCDs and Cardiovascular Diseases: The Global Status 327 $a1.4.2 The Status of Cardiovascular Diseases in the United States1.4.3 The Status of Cardiovascular Diseases in China; 1.5 Risk Factors of Cardiovascular Diseases; 1.5.1 Classification of Cardiovascular Disease Risk Factors; 1.5.2 Major Cardiovascular Disease Risk Factors and Their Impact; 1.6 Prevention and Control of Cardiovascular Diseases; 1.6.1 The UN High-Level Meeting and Tackling Cardiovascular Diseases at the Global Level; 1.6.2 The World Heart Federation Call to Action to Prevent and Control Cardiovascular Diseases 327 $a1.6.3 The AHA 2010 Health Impact Goal, 2020 Health Impact Goal, and Ideal Cardiovascular Health1.6.4 US DHSS "Million Hearts" Initiative; 1.7 Cardiovascular Risk Prediction and Evidence-based Treatments; 1.7.1 Cardiovascular Risk Prediction; 1.7.2 Evidence-Based Treatments; 1.8 Summary of Chapter Key Points; 1.9 Self-Assessment Questions; References; Chapter 2 Introduction to Principles of Pharmacology; 2.1 Overview; 2.2 Definitions and History; 2.2.1 What Is Pharmacology?; 2.2.2 Definitions of Related Terms; 2.2.3 A Brief History of Pharmacology 327 $a2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology2.3.1 Drug Names, Sources, Preparations, and Administration; 2.3.2 Pharmacokinetics; 2.3.3 Pharmacodynamics; 2.3.4 Drug Toxicity; 2.3.5 Pharmacogenetics and Pharmacogenomics; 2.4 Principles of Drug Discovery, Development, and Regulation; 2.4.1 Definitions; 2.4.2 The Paradigm of Drug Creation and Survival; 2.4.3 The FDA Drug Review and Approval Process; 2.5 Pharmacology Subspecialties; 2.6 Introduction to Cardiovascular Pharmacology; 2.6.1 Definition and Scope; 2.6.2 New Developments and Challenges 327 $a2.6.3 Systems Pharmacology in the Management of Cardiovascular Diseases2.6.4 Polypill for the Management of Cardiovascular Diseases; 2.6.5 Protein Therapeutics of Cardiovascular Diseases; 2.6.6 Gene Therapy of Cardiovascular Diseases; 2.6.7 Stem Cell Therapy of Cardiovascular Diseases; 2.7 Summary of Chapter Key Points; 2.8 Self-Assessment Questions; References; Unit II Dyslipidemias; Chapter 3 Overview of Dyslipidemias and Drug Therapy; 3.1 Introduction; 3.2 Lipoprotein Metabolism; 3.2.1 Definition, Structure, and Classification of Lipoproteins 327 $a3.2.2 Metabolic Pathways of Lipoproteins and Drug Therapy 330 $aWritten in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases. Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases Facilitates understanding of drug action and mechanism by covering physiology / pathophysiology and pharmacology Includes guidelines and algorithms for pharmac 606 $aCardiovascular system$xDiseases$xChemotherapy 606 $aCardiovascular system$xDiseases$xDiagnosis 608 $aElectronic books. 615 0$aCardiovascular system$xDiseases$xChemotherapy. 615 0$aCardiovascular system$xDiseases$xDiagnosis. 676 $a616.1/061 700 $aLi$b Robert Y.$0866523 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910460135303321 996 $aCardiovascular diseases$91934012 997 $aUNINA